The adjusted prevalence of increased ALT, increased AST, and liver injury in the COVID-19 patients were all decreased, which indicates that the overall prevalence of hypertransaminemia and liver injury in patients with COVID-19 might be overestimated. Here, GPT is linked to COVID-19.